These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 25801501)
1. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501 [TBL] [Abstract][Full Text] [Related]
2. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. Roche DJO; Worley MJ; Courtney KE; Bujarski S; London ED; Shoptaw S; Ray LA Psychopharmacology (Berl); 2017 Jul; 234(13):1997-2007. PubMed ID: 28357460 [TBL] [Abstract][Full Text] [Related]
3. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Li MJ; Chau B; Belin T; Carmody T; Jha MK; Marino EN; Trivedi M; Shoptaw SJ Addiction; 2024 Oct; 119(10):1840-1845. PubMed ID: 38856086 [TBL] [Abstract][Full Text] [Related]
4. Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine. Marks KR; Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR J Clin Psychopharmacol; 2016 Jun; 36(3):213-21. PubMed ID: 27043121 [TBL] [Abstract][Full Text] [Related]
5. Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses. Lim AC; Grodin EN; Green R; Venegas A; Meredith LR; Courtney KE; Moallem NR; Sayegh P; London ED; Ray LA Am J Drug Alcohol Abuse; 2020 Sep; 46(5):565-576. PubMed ID: 32343625 [No Abstract] [Full Text] [Related]
6. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Comer SD; Mogali S; Saccone PA; Askalsky P; Martinez D; Walker EA; Jones JD; Vosburg SK; Cooper ZD; Roux P; Sullivan MA; Manubay JM; Rubin E; Pines A; Berkower EL; Haney M; Foltin RW Neuropsychopharmacology; 2013 Nov; 38(12):2427-38. PubMed ID: 23736314 [TBL] [Abstract][Full Text] [Related]
8. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846 [TBL] [Abstract][Full Text] [Related]
9. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Kohno M; Dennis LE; McCready H; Schwartz DL; Hoffman WF; Korthuis PT Drug Alcohol Depend; 2018 Nov; 192():186-192. PubMed ID: 30266003 [TBL] [Abstract][Full Text] [Related]
10. The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans. Courtney KE; Ghahremani DG; Ray LA Neuropsychopharmacology; 2016 Nov; 41(12):2872-2881. PubMed ID: 27312405 [TBL] [Abstract][Full Text] [Related]
11. Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study. Guterstam J; Jayaram-Lindström N; Berrebi J; Petrovic P; Ingvar M; Fransson P; Franck J Drug Alcohol Depend; 2018 Oct; 191():91-97. PubMed ID: 30096639 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials. Lam L; Anand S; Li X; Tse ML; Zhao JX; Chan EW Clin Toxicol (Phila); 2019 Apr; 57(4):225-233. PubMed ID: 30451013 [TBL] [Abstract][Full Text] [Related]
13. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819 [TBL] [Abstract][Full Text] [Related]
14. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. Pal R; Mendelson JE; Flower K; Garrison K; Yount G; Coyle JR; Galloway GP J Addict Med; 2015; 9(2):130-5. PubMed ID: 25622123 [TBL] [Abstract][Full Text] [Related]
15. Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients. Spagnolo PA; Ramchandani VA; Schwandt ML; Zhang L; Blaine SK; Usala JM; Diamond KA; Phillips MJ; George DT; Momenan R; Heilig M Alcohol Clin Exp Res; 2014 Dec; 38(12):3024-32. PubMed ID: 25581657 [TBL] [Abstract][Full Text] [Related]
16. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Krishnan-Sarin S; O'Malley SS; Franco N; Cavallo DA; Tetrault JM; Shi J; Gueorguieva R; Pittman B; Krystal JH Neuropsychopharmacology; 2020 Jan; 45(2):319-326. PubMed ID: 31590179 [TBL] [Abstract][Full Text] [Related]
17. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Jayaram-Lindström N; Hammarberg A; Beck O; Franck J Am J Psychiatry; 2008 Nov; 165(11):1442-8. PubMed ID: 18765480 [TBL] [Abstract][Full Text] [Related]
18. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107 [TBL] [Abstract][Full Text] [Related]
19. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Johnson BA; Roache JD; Ait-Daoud N; Wells LT; Wallace CL; Dawes MA; Liu L; Wang XQ Int J Neuropsychopharmacol; 2007 Feb; 10(1):85-98. PubMed ID: 16448579 [TBL] [Abstract][Full Text] [Related]
20. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Sinha R; Kimmerling A; Doebrick C; Kosten TR Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]